Department of Neurosurgery, School of Medicine, Fırat University, Elazig, Turkey.
Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
World Neurosurg. 2021 Oct;154:e495-e508. doi: 10.1016/j.wneu.2021.07.070. Epub 2021 Jul 22.
Deep brain stimulation (DBS) is a frequently applied therapy in primary dystonia. For secondary dystonia, the effects can be less favorable. We share our long-term findings in 9 patients with severe secondary dystonia and discuss these findings in the light of the literature.
Patients who had undergone globus pallidus internus (GPi)-DBS for secondary dystonia were included. Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) scores, clinical improvement rates, follow-up periods, stimulation parameters and the need for internal pulse generator replacements were analyzed. The PubMed and Google Scholar databases were searched for articles describing GPi-DBS and subthalamic nucleus (STN)-DBS only for secondary dystonia cases. Keywords were "dystonia," "deep brain stimulation," "GPi," "dystonia," "deep brain stimulation," and "STN."
A total of 9 secondary dystonia patients (5 male, 4 female) had undergone GPi-DBS with microelectrode recording in our units. The mean follow-up period was 29 months. The average BFMDRS score was 58.2 before the surgery, whereas the mean value was 36.5 at the last follow-up of the patients (mean improvement, 39%; minimum, 9%; maximum, 63%). In the literature review, we identified 264 GPi-DBS cases (mean follow-up, 19 months) in 72 different articles about secondary dystonia. The mean BFMDRS improvement rate was 52%. In 146 secondary dystonia cases, reported in 19 articles, STN-DBS was performed. The average follow-up period was 20 months and the improvement in BFMDRS score was 66%.
Although GPi-DBS has favorable long-term efficacy and safety in the treatment of patients with secondary dystonia, STN seems a promising target for stimulation in patients with secondary dystonia. Further studies including a large number of patients, longer follow-up periods, and more homogenous patients are necessary to establish the optimal target for DBS in the management of secondary dystonias.
深部脑刺激(DBS)是原发性肌张力障碍的常用治疗方法。对于继发性肌张力障碍,效果可能不太理想。我们分享了 9 例严重继发性肌张力障碍患者的长期发现,并结合文献对这些发现进行了讨论。
纳入接受苍白球内侧(GPi)-DBS 治疗继发性肌张力障碍的患者。分析 Burke-Fahn-Marsden 肌张力障碍评定量表(BFMDRS)评分、临床改善率、随访时间、刺激参数和内部脉冲发生器更换需求。在 PubMed 和 Google Scholar 数据库中搜索仅描述 GPi-DBS 和丘脑底核(STN)-DBS 治疗继发性肌张力障碍的文章。关键词为“肌张力障碍”、“深部脑刺激”、“GPi”、“肌张力障碍”、“深部脑刺激”和“STN”。
共有 9 例(5 例男性,4 例女性)继发性肌张力障碍患者在我院接受了 GPi-DBS 治疗,其中 8 例行微电极记录。平均随访时间为 29 个月。患者术前平均 BFMDRS 评分为 58.2,末次随访时平均评分为 36.5(平均改善率为 39%,最小改善率为 9%,最大改善率为 63%)。在文献复习中,我们在 72 篇关于继发性肌张力障碍的不同文章中确定了 264 例 GPi-DBS 病例(平均随访时间 19 个月)。平均 BFMDRS 改善率为 52%。在 19 篇文章中报道的 146 例继发性肌张力障碍患者中,进行了 STN-DBS。平均随访时间为 20 个月,BFMDRS 评分改善率为 66%。
尽管 GPi-DBS 治疗继发性肌张力障碍具有良好的长期疗效和安全性,但 STN 似乎是刺激治疗继发性肌张力障碍的有前途的靶点。需要进一步研究,包括大量患者、更长的随访时间和更同质的患者,以确定 DBS 在继发性肌张力障碍管理中的最佳靶点。